Literature DB >> 1814610

Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins.

S Sawada1, S Matsuoka, K Nokata, H Nagata, T Furuta, T Yokokura, T Miyasaka.   

Abstract

20(S)-Camptothecin derivatives having nitro, amino, chloro, bromo, hydroxyl and methoxyl groups in the A-ring were synthesized. B-Ring hydrogenated camptothecin (2a) was converted into 10-hydroxycamptothecin (6e) by treatment with lead tetraacetate in trifluoroacetic acid. 10-Substituted derivatives (6) were obtained by a photoreaction of N-oxides (9). The cytotoxicity of the A-ring modified camptothecins was evaluated against KB cells in vitro and leukemia L1210 in mice. 7-Ethyl-10-hydroxycamptothecin (6i) was identified as a potential derivative for further modification.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814610     DOI: 10.1248/cpb.39.3183

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  8 in total

1.  MM3(96) parameterization for camptothecin analogs: an ab initio and molecular mechanics study.

Authors:  S W Carrigan; J H Lii; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

2.  Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.

Authors:  S W Carrigan; P C Fox; M E Wall; M C Wani; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

3.  A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.

Authors:  Peter C Enzinger; Matthew H Kulke; Jeffrey W Clark; David P Ryan; Haesook Kim; Craig C Earle; Michele M Vincitore; Ann L Michelini; Robert J Mayer; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 4.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

Review 5.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

Review 6.  Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

Authors:  Vincent J Venditto; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

7.  Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.

Authors:  Hiroki Ide; Eiji Kikuchi; Masanori Hasegawa; Seiya Hattori; Yota Yasumizu; Akira Miyajima; Mototsugu Oya
Journal:  Cancer Med       Date:  2013-06-10       Impact factor: 4.452

Review 8.  Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.

Authors:  Mateusz Kciuk; Beata Marciniak; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.